Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Top Cited Papers
- 1 October 2017
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 17 (10), 1062-1068
- https://doi.org/10.1016/s1473-3099(17)30496-6
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology, 2015
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 InfectionAnnals of Internal Medicine, 2015
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisHepatology, 2015
- Hepatitis CThe Lancet, 2015
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resourceHepatology, 2013
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patientsGastroenterology, 1997